Anti-EphA2 chimeric antigen receptor T cell therapy - Yake Biotechnology
Alternative Names: EphA2 targeting CAR-T cell therapy - Yake BiotechnologyLatest Information Update: 20 Apr 2021
Price :
$50 *
At a glance
- Originator Yake Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Lung cancer
Most Recent Events
- 01 Apr 2021 Preclinical trials in Lung cancer in China (Parenteral) (Yake Biotechnology pipeline, April 2021)